Journal of Immunotoxicology,
Journal Year:
2024,
Volume and Issue:
21(1)
Published: Nov. 1, 2024
Nanoparticles
are
commonly
used
in
diagnostics
and
therapy.
They
also
increasingly
being
implemented
cancer
immunotherapy
because
of
their
ability
to
deliver
drugs
modulate
the
immune
system.
However,
effect
nanoparticles
on
cells
involved
anti-tumor
response
is
not
well
understood.
The
study
reported
here
showed
that
nickel-doped
maghemite
(FN
NP)
differentially
cytotoxic
cultured
mouse
human
cell
lines,
causing
death
without
negatively
impacting
subsequent
anticancer
response.
It
found
FN
NP
induced
colorectal
line
CT26
prostate
PC-3,
but
LNCaP.
did
affect
phenotype
responsivity
isolated
peritoneal
macrophages,
or
ex
vivo-generated
bone
marrow-derived,
monocyte-derived
dendritic
cells.
Additionally,
prevent
from
stimulating
lymphocytes
enriching
cultures
with
cell-reactive
T-cells.
In
conclusion,
this
shows
could
be
a
valuable
platform
for
targeting
immunosuppressive
effects
International Journal of Molecular Sciences,
Journal Year:
2025,
Volume and Issue:
26(4), P. 1613 - 1613
Published: Feb. 14, 2025
The
combination
of
chemotherapeutic
agents
with
immune
checkpoint
inhibitors
(ICIs)
has
revolutionized
cancer
treatment.
However,
its
success
is
often
limited
by
insufficient
priming
in
certain
tumors,
including
pediatric
malignancies.
In
this
report,
we
explore
clinical
trials
currently
investigating
the
use
immunogenic
cell
death
(ICD)-inducing
chemotherapies
ICIs
for
both
adult
and
cancers.
Given
data
available
focused
on
recent
preclinical
studies
evaluating
efficacy
these
combinations
neuroblastoma
(NB).
Finally,
to
address
gap,
propose
an
innovative
strategy
assess
impact
ICD-inducing
antitumor
responses
NB.
Using
tumor
spheroids
derived
from
a
transgenic
NB
mouse
model,
validated
our
previous
vivo
findings
concerning
how
anthracyclines,
specifically
mitoxantrone
doxorubicin,
significantly
enhance
MHC
class
I
surface
expression,
stimulate
IFNγ
granzyme
B
production
CD8+
T
cells
NK
cells,
promote
recruitment.
Importantly,
anthracyclines
also
upregulated
PD-L1
expression
spheroids.
This
screening
platform
yielded
results
similar
findings,
demonstrating
that
doxorubicin
are
most
potent
immunomodulatory
These
suggest
creation
libraries
ICD
inducers
be
tested
could
reduce
number
vivo,
line
principles
3Rs.
Furthermore,
highlight
potential
chemo-immunotherapy
regimens
counteract
immunosuppressive
microenvironment
NB,
paving
way
improved
therapeutic
strategies
They
provide
compelling
evidence
support
further
investigations
outcomes
children
Journal of Translational Internal Medicine,
Journal Year:
2025,
Volume and Issue:
13(1), P. 10 - 32
Published: Feb. 1, 2025
In
the
evolving
landscape
of
cancer
treatment,
strategic
manipulation
regulated
cell
death
(RCD)
pathways
has
emerged
as
a
crucial
component
effective
anti-tumor
immunity.
Evidence
suggests
that
tumor
cells
undergoing
RCD
can
modify
immunogenicity
microenvironment
(TME),
potentially
enhancing
its
ability
to
suppress
progression
and
metastasis.
this
review,
we
first
explore
mechanisms
apoptosis,
necroptosis,
pyroptosis,
ferroptosis,
cuproptosis,
along
with
crosstalk
between
these
modalities.
We
then
discuss
how
processes
activate
antigen-presenting
cells,
facilitate
cross-priming
CD8+
T
trigger
immune
responses,
highlighting
complex
effects
novel
forms
on
TME
biology.
Furthermore,
summarize
potential
drugs
nanoparticles
induce
or
inhibit
emerging
their
therapeutic
roles
in
treatment.
Finally,
put
forward
existing
challenges
future
prospects
for
targeting
anti-cancer
Overall,
review
enhances
our
understanding
molecular
biological
impacts
RCD-based
therapies,
providing
new
perspectives
strategies
Frontiers in Immunology,
Journal Year:
2025,
Volume and Issue:
15
Published: Jan. 23, 2025
Cancer
immunotherapy
has
shown
significant
potential
in
treating
several
malignancies
by
stimulating
the
host
immune
system
to
recognize
and
attack
cancer
cells.
Immunogenic
cell
death
(ICD)
can
amplify
antitumor
responses
reverse
immunosuppressive
tumor
microenvironment,
thus
increasing
sensitivity
of
immunotherapy.
In
recent
years,
noncoding
RNAs
(ncRNAs)
have
emerged
as
key
regulatory
factors
ICD
oncologic
immunity.
Accordingly,
ICD-related
ncRNAs
hold
promise
novel
therapeutic
targets
for
optimizing
efficacy
However,
immunomodulatory
properties
not
yet
been
comprehensively
summarized.
Hence,
we
summarize
current
knowledge
on
involved
their
roles
this
review.
It
deepens
our
understanding
associated
with
provides
a
new
strategy
enhance
specifically
targeting
ncRNAs.
Journal of drug targeting,
Journal Year:
2025,
Volume and Issue:
unknown, P. 1 - 43
Published: Feb. 19, 2025
In
the
dynamic
arena
of
cancer
therapeutics,
chemoimmunotherapy
has
shown
tremendous
promise,
especially
for
aggressive
forms
breast
like
triple-negative
(TNBC).
This
review
delves
into
significant
role
liposomes
in
enhancing
effectiveness
by
leveraging
cancer-specific
mechanisms
such
as
induction
immunogenic
cell
death
(ICD),
reprogramming
tumor
microenvironment
(TME),
and
enabling
sequential
drug
release.
We
examine
innovative
dual-targeting
that
capitalize
on
heterogeneity,
well
pH-sensitive
formulations
offer
improved
control
over
delivery.
Unlike
prior
analyses,
this
directly
links
advancements
preclinical
research-such
PAMAM
dendrimer-based
nanoplatforms
RGD-decorated
liposomes-to
clinical
trial
results,
highlighting
their
potential
to
revolutionize
TNBC
treatment
strategies.
Additionally,
we
address
ongoing
challenges
related
scalability,
toxicity,
regulatory
compliance,
propose
future
directions
personalized,
immune-focused
nanomedicine.
work
not
only
synthesizes
latest
research
but
also
offers
a
framework
translating
liposomal
from
laboratory
practice.
Critical Reviews in Oncology/Hematology,
Journal Year:
2025,
Volume and Issue:
210, P. 104700 - 104700
Published: March 12, 2025
Cancer
immunotherapy
has
become
a
revolutionary
strategy
in
oncology,
utilizing
the
host
immune
system
to
fight
malignancies.
Notwithstanding
major
progress,
obstacles
such
as
evasion
by
tumors
and
development
of
resistance
still
remain.
This
manuscript
examines
function
chaperone-mediated
autophagy
(CMA)
cancer
biology,
focusing
on
its
effects
tumor
response
resistance.
CMA
is
selective
degradation
mechanism
for
cytosolic
proteins,
which
crucial
sustaining
cellular
homeostasis
regulating
responses.
By
degrading
specific
can
either
facilitate
progression
stressful
conditions,
or
promote
suppression
removing
oncogenic
factors.
double-edged
sword
highlights
complexity
possible
effect
treatment
results.
Here
we
clarify
molecular
mechanisms
regulate
role
therapeutic
target
improving
effectiveness
immunotherapy.
Human Vaccines & Immunotherapeutics,
Journal Year:
2025,
Volume and Issue:
21(1)
Published: April 5, 2025
Apoptosis
is
vital
for
improving
the
efficacy
of
lung
cancer
(LC)
immunotherapy
by
targeting
cell
elimination.
Despite
its
importance,
there
a
lack
comprehensive
bibliometric
studies
analyzing
global
research
on
apoptosis
in
LC
immunotherapy.
This
analysis
aims
to
address
this
gap
highlighting
key
trends,
contributors,
and
future
directions.
A
total
969
publications
from
1996
2024
were
extracted
Web
Science
Core
Collection.
Analysis
was
conducted
using
VOSviewer,
CiteSpace,
R
package
'bibliometrix.'
The
study
included
contributions
6,894
researchers
across
1,469
institutions
61
countries,
with
published
356
journals.
volume
has
steadily
increased,
led
China
United
States,
Sichuan
University
as
top
contributor.
journal
Cancers
most
articles,
while
Cancer
Research
had
highest
co-citations.
Yu-Quan
Wei
leading
author,
Jemal,
A.
frequently
co-cited.
Key
themes
include
"cell
death
mechanisms,"
"immune
regulation,"
"combination
therapies,"
"gene
nanomedicine
applications,"
"traditional
Chinese
medicine
(TCM)."
Future
likely
focus
"coordinated
regulation
multiple
pathways,"
"modulation
tumor
immune
microenvironment,"
"optimization
combination
"novel
strategies
gene
"integration
TCM"
personalized
treatment.
first
role
immunotherapy,
providing
an
landscape
patterns
emerging
therapeutic
strategies.
findings
offer
insights
guide
optimize
treatment
approaches.